CD274 and neoplasm: In a CT26 colon carcinoma model with high IDO1 activity, PF-06840003 can reduce over 80% intratumoral kynurenine levels and inhibited tumor growth both in monotherapy and, with an increased efficacy, in combination with a humanized anti-PD-L1 antibody avelumab 48.